(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 November 2015 (26.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/179724 A9

(51) **International Patent Classification**:
C12N 15/113 (2010.01) *A61K 31/712* (2006.01)
A61P 9/00 (2006.01)

(21) **International Application Number**:
PCT/US2015/032099

(22) **International Filing Date**:
22 May 2015 (22.05.2015)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
62/001,731 22 May 2014 (22.05.2014) US
62/047,978 9 September 2014 (09.09.2014) US

(71) **Applicant**: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) **Inventors**: **FOSTER, Donald**; 300 Third Street, Cambridge, MA 02142 (US). **BETTENCOURT, Brian**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **CHARISSE, Klaus**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **HINKLE, Gregory**; 300 Third Street, Cambridge, MA 02142 (US). **KUCHIMANCHI, Satyanarayana**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MAIER, Martin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MILSTEIN, Stuart**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(74) **Agents**: **ZACHARAKIS, Maria, Laccotripe** et al.; Mccarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) **Title**: ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF




FIG. 1

(57) **Abstract**: The present invention relates to RNAi agents, e.g., double- stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

WO 2015/179724 A9

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
10 March 2016

(15) Information about Corrections:
see Notice of 10 March 2016

Previous Correction:
see Notice of 18 February 2016